Table 1. Literature review.
Type (number) of studies | Number of patients per study | Prognostic factors reported (frequency of reporting) | U or MV analysis | ||
---|---|---|---|---|---|
Randomised controlled trial (n=4)3–6 | 207–322 | Surgical | Metastases | (3) | 4 MV |
Tumour location | (1) | ||||
Clinical | Performance status | (3) | |||
Treatment | (1) | ||||
Laboratory | Alkaline phosphatase | (1) | |||
Consecutive series >500 patients (n=3)7–9 | 782–2380 | Surgical | Metastases | (1) | 2 MV |
Stage of disease | (1) | 1 U | |||
Operation | (1) | ||||
Clinical | Performance status | (1) | |||
Diabetes | (1) | ||||
Pain | (1) | ||||
Appetite/weight | (1) | ||||
Jaundice | (1) | ||||
Treatment | (1) | ||||
Laboratory | Albumin | (1) | |||
Demographic | Age | (1) | |||
Specialist centre | (1) | ||||
Consecutive series 100–500 patients (n=14)10–23 | 102–450 | Surgical | Metastases | (4) | 13 MV |
Stage of disease | (2) | 1 U | |||
Tumour location | (1) | ||||
Operation | (2) | ||||
Tumour size | (1) | ||||
Duodenal invasion | (1) | ||||
Peridissemination | (1) | ||||
Ascites | (1) | ||||
Clinical | Performance status | (2) | |||
Diabetes | (1) | ||||
Pain | (1) | ||||
Appetite/weight | (3) | ||||
Symptom onset | (1) | ||||
Treatment | (2) | ||||
Laboratory | CA242 | (2) | |||
CA19-9 | (2) | ||||
Leukocytes | (1) | ||||
Gamma GT | (1) | ||||
Albumin | (1) | ||||
LDH | (1) | ||||
CRP | (3) | ||||
Iron | (1) | ||||
Demographic | Age | (1) | |||
Consecutive series | 28–95 | Surgical | Metastases | (1) | 8 MV |
<100 patients (n=15)24–38 | Stage of disease | (1) | 7 U | ||
Grade of disease | (1) | ||||
Nodal status | (1) | ||||
Operation | (1) | ||||
Tumour size | (2) | ||||
Fibrosis | (1) | ||||
Clinical | Performance status Inflammation | (4) | |||
Appetite/weight | (1) | ||||
Treatment | (1) | ||||
Laboratory | CA19-9 | (1) | |||
VEGF | (7) | ||||
CEA | (1) | ||||
Phase angle BIA | (1) | ||||
SCA | (1) | ||||
(1) |
MV=multivariate; U=univariate.